Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

AbbVie gains EU approval of atogepant for acute migraine

Summary by Seeking Alpha
EU approves AbbVie’s Aquipta (atogepant) as an acute migraine treatment. Read more here.

3 Articles

Seeking AlphaSeeking Alpha
Lean Right

AbbVie gains EU approval of atogepant for acute migraine

EU approves AbbVie’s Aquipta (atogepant) as an acute migraine treatment. Read more here.

·United States
Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com
Reposted by
Pharmaceutical Business reviewPharmaceutical Business review

AbbVie receives EC approval for Aquipta to treat migraine

AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in United States on Tuesday, June 2, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

European Union icon

European Union

AbbVie icon

AbbVie

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal